InnovHeart

Focus: InnovHeart is a cardiovascular biotechnology company focused on atrioventricular valve replacement technologies, headquartered in Milan, Italy. The company specializes in transcatheter and surgical mitral valve solutions for conditions like mitral regurgitation and heart failure.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About InnovHeart

AI assessmentNot Hiring

No open roles listed right now. Follow InnovHeart to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Transcatheter mitral valve replacement

Heart Failure

N/A

Clinical Trials (1)

NCT06414265Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation

N/A

Help build intelligence for InnovHeart

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need cardiovascular space with three active programs targeting mitral valve pathology
Early-stage company offers ground-floor opportunity to build expertise in transcatheter valve technologies, a fast-growing sector
Milan headquarters provides access to European clinical networks and regulatory pathways

Watch Out For

No current open positions advertised and no hiring department data signals potential constraints on growth or expansion plans
Absence of published financials, funding details, and development stage creates uncertainty about company viability and runway
Pre-revenue status with three early-stage programs means long timeline to value creation and significant commercial execution risk

Generated by Claude from InnovHeart's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

SATURN TA System

Mitral Regurgitation

N/A

Clinical Trials (1)

NCT04464876SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

N/A

Mitral Valve Replacement

Mitral Regurgitation

N/A

Clinical Trials (1)

NCT07130994Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline